Novavax stock jumps after submission of data on COVID-19 vaccine candidate to Health Canada, EMA completed

Shares of Novavax Inc. NVAX, -1.19% changeable up 6.8% successful premarket trading Monday, aft the biotechnology institution said it has completed its rolling submission to Canada's wellness authorities, Health Canada, for the authorization of its COVID-19 vaccine candidate. The institution said it has besides completed the submission of each information to the European Medicines Agency (EMA) for regulatory review. The institution said the last measurement for applying for EMA authorization is an invitation from EMA to record for Conditional Marketing Authorization. "Novavax continues to present regulatory filings that we expect volition bring the archetypal protein-based COVID-19 vaccine based connected Phase 3 information to the world," said Novavax Chief Executive Stanley Erck. "We convey the Government of Canada and the European Commission for their ongoing concern and assurance successful our COVID-19 vaccine program." The banal has tumbled 17.0% implicit the past 3 months done Friday, portion the iShares Biotechnology ETF IBB, -0.37% has slipped 3.7% and the S&P 500 SPX, +0.19% has gained 4.8%.